What is the appropriate dosing regimen for valacyclovir in adults, including adjustments for renal impairment?

Valacyclovir Dosing in Adults

For immunocompetent adults with normal renal function, valacyclovir dosing varies by indication: 500 mg twice daily for 5 days for episodic genital herpes recurrences, 1000 mg three times daily for 7-10 days for herpes zoster, and 2 grams twice daily for 1 day for cold sores. 1, 2

Dosing by Indication (Normal Renal Function)

Genital Herpes

• Episodic recurrent infection: 500 mg orally twice daily for 5 days 1
• Suppressive therapy:
  • Standard: 500 mg once daily OR 1000 mg once daily 1
  • Alternative: 250 mg twice daily 1
  • Important caveat: 500 mg once daily is less effective in patients with ≥10 recurrences per year; use higher doses in this population 1

Herpes Zoster (Shingles)

• Standard dose: 1000 mg orally three times daily (every 8 hours) for 7-10 days 2
• Initiate within 48 hours of rash onset for maximum efficacy 2

Cold Sores (Herpes Labialis)

• Single-day therapy: 2 grams twice daily for 1 day (doses separated by 12 hours) 2
• Start at earliest symptom (tingling, itching, burning) 2

HSV Encephalitis

• High-dose regimen: 2 grams three times daily for extended duration (under investigation) 3
• Note: IV acyclovir remains standard for proven HSV encephalitis (10 mg/kg every 8 hours for 14-21 days) 3

HIV-Infected Patients

• Suppressive therapy: 500 mg twice daily (NOT once daily) 4
• Higher doses may be needed for severe episodes; clinical experience suggests 400-500 mg three to five times daily may be beneficial 1

Renal Dose Adjustments (Critical)

Valacyclovir requires mandatory dose reduction in renal impairment to prevent neurotoxicity, which can occur in up to 20% of patients with inadequate adjustment. 3, 5, 6, 7

Creatinine Clearance-Based Dosing 5, 2

For Herpes Zoster (1000 mg TID baseline):

• CrCl 30-49 mL/min: 1000 mg every 12 hours
• CrCl 10-29 mL/min: 1000 mg every 24 hours
• CrCl <10 mL/min: 500 mg every 24 hours

For Genital Herpes Treatment (500 mg BID baseline):

• CrCl 30-49 mL/min: No reduction needed
• CrCl 10-29 mL/min: 500 mg every 24 hours
• CrCl <10 mL/min: 500 mg every 24 hours

For Suppressive Therapy (1000 mg daily baseline):

• CrCl 30-49 mL/min: No reduction needed
• CrCl 10-29 mL/min: 500 mg every 24 hours
• CrCl <10 mL/min: 500 mg every 24 hours

For Cold Sores (2000 mg BID × 1 day baseline):

• CrCl 30-49 mL/min: 1000 mg every 12 hours for 1 day
• CrCl 10-29 mL/min: 500 mg every 24 hours for 1 day
• CrCl <10 mL/min: 500 mg single dose

Hemodialysis Patients

• Administer recommended dose after hemodialysis 2
• Approximately one-third of acyclovir is removed during a 4-hour dialysis session 2

Peritoneal Dialysis Patients

• No supplemental dosing required after CAPD or CAVHD 2
• Use end-stage renal disease dosing recommendations 2

Critical Safety Considerations

Neurotoxicity Risk

CNS disturbance occurs more frequently with acyclovir/valacyclovir than famciclovir, particularly in renal impairment, with risk differences of 1.96% in dialysis patients. 6, 7

Warning signs of neurotoxicity include:

• Mental confusion, psychomotor agitation
• Hallucinations, dysarthria
• Tremors, myoclonus, seizures
• Ataxia, paresis
• Symptoms typically appear 2-4 days after treatment initiation 7

Management: Discontinue immediately; symptoms resolve gradually after cessation 7

Renal Toxicity

• Crystalluria causing obstructive nephropathy can occur, typically after 4+ days of IV therapy 3
• Affects up to 20% of patients on IV acyclovir 3
• Prevention: Maintain adequate hydration 8
• Rarely seen with oral valacyclovir except in overdosage 3

Thrombotic Microangiopathy

• Reported with high-dose valacyclovir (8 grams/day) in HIV patients with advanced disease 1, 4
• Not reported at standard therapeutic doses for HSV treatment 4

Special Populations

Elderly Patients

• Acyclovir half-life increases from 2.91 to 3.11 hours 2
• Dose reduction required based on renal function, which commonly declines with age 2
• Calculate creatinine clearance; don't rely on serum creatinine alone

Pregnancy

• Safety not fully established 1
• First-episode genital herpes during pregnancy may be treated with oral acyclovir/valacyclovir 1
• High-dose valacyclovir for CMV prevention carries ~1% risk of acute kidney injury 9

Hepatic Impairment

• No dose adjustment needed in cirrhosis 2
• Rate (but not extent) of conversion to acyclovir is reduced 2

Common Prescribing Errors

Real-world data shows 25.1% overdosing rate in patients with impaired renal function receiving high-dose regimens for zoster, with higher rates in women and community pharmacy settings. 10

To avoid errors:

1. Always calculate creatinine clearance before prescribing
2. Use Cockcroft-Gault equation (preferred for drug dosing)
3. Verify dose against renal function tables
4. Monitor renal function during treatment if baseline impairment exists
5. Educate patients on hydration importance

Monitoring Requirements

• Baseline: Serum creatinine, calculate CrCl
• During treatment:
  • Renal function monitoring if baseline impairment present
  • Watch for neurological symptoms (confusion, tremor, hallucinations)
  • No routine laboratory monitoring needed for episodic/suppressive therapy in normal renal function 4